Ranibizumab "Treat and Extend" in Diabetic Macular Edma

Sponsor
Novartis Pharmaceuticals
Study ID
NCT01297569
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to diabetic macular edema.

Key Dates

First listed
Feb 16, 2011
Start date
Jan 31, 2011
Status verified
Feb 2017
Primary completion
Nov 30, 2012
Completion
Nov 30, 2012

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ranibizumab

Primary Outcome Measure

Change in Best Corrected Visual Acuity(BCVA) [ Time Frame: from month 0 (baseline) to month 12 ]

Related Studies